Current Clinical Trials

Sneeze, Wheeze and Itch Associates, LLC

Go Back

Chronic Refractory Cough

  • Number
  • Type
  • Age Range
  • Length of Study
  • Compensation*
  • 1812VA323
  • Chronic Refractory Cough
  • 18 - 80 years of age
  • ~ 10 weeks
  • $450


*Qualified participants may receive compensation for time and travel, up to the amount listed.

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-selection Study of S-600918 in Patients With Refractory Chronic Cough

The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo..

Key Inclusion Criteria:

  • Having refractory chronic cough (including unexplained chronic cough) for at least 1 year.
  • If female and of childbearing potential, agreement to use one of the allowed contraceptive methods.
  • Capable of giving signed informed consent.

Key Exclusion Criteria:

  • Currently smokes or uses potentially irritating inhalational agents (eg, e-cigarettes, smokeless cigarettes, vaping); stopped smoking or using potentially irritating inhalational agents within the last year; or has a smoking history of 20 pack-years or more.
  • Has chronic obstructive pulmonary disease or uncontrolled asthma.
  • Has a clinically unstable medical condition.
  • History of or ongoing significant psychiatric disorder.
  • History of respiratory tract infection or significant change in lung function or a pulmonary condition in the last 4 weeks.
  • History of malignancy in the last 5 years.
  • History of severe drug allergy.
  • History of alcohol or drug abuse in the last year or currently uses any form of marijuana or illicit drugs.
  • Has a clinically significant finding on a chest x-ray or chest computed tomography (CT) scan in the last year.
  • Has systolic blood pressure > 160 mm Hg or diastolic blood pressure > 90 mm Hg.
  • Received S-600918 previously.
  • Received an investigational drug in the last 3 months.
  • Received an angiotensin converting enzyme (ACE) inhibitor in the last 3 months or requires such treatment.
  • Has a positive serologic test for human immunodeficiency virus (HIV) antigen or antibody, hepatitis B virus surface antigen, or hepatitis C virus ribonucleic acid (RNA).
  • If female, pregnant or trying to become pregnant or breastfeeding.

For more information, please call 309-452-0995 and ask to speak to a coordinator.